AR105616A1 - Proteínas de fusión - Google Patents
Proteínas de fusiónInfo
- Publication number
- AR105616A1 AR105616A1 ARP160101082A ARP160101082A AR105616A1 AR 105616 A1 AR105616 A1 AR 105616A1 AR P160101082 A ARP160101082 A AR P160101082A AR P160101082 A ARP160101082 A AR P160101082A AR 105616 A1 AR105616 A1 AR 105616A1
- Authority
- AR
- Argentina
- Prior art keywords
- absent
- amino acid
- insulin
- fusion protein
- peptide linker
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 102000037865 fusion proteins Human genes 0.000 title abstract 5
- 150000001413 amino acids Chemical group 0.000 abstract 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 6
- 102000004877 Insulin Human genes 0.000 abstract 4
- 108090001061 Insulin Proteins 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 229940125396 insulin Drugs 0.000 abstract 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 abstract 2
- 229940079288 Insulin receptor agonist Drugs 0.000 abstract 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 229910052698 phosphorus Inorganic materials 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000000710 homodimer Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Abstract
Reivindicación 1: Una proteína de fusión que comprende: a) un agonista del receptor de insulina que tiene la fórmula general: Z¹-Z²-Z³, en la que: i) Z¹ es un análogo de la cadena B de insulina, que comprende la secuencia de aminoácidos: X¹X²X³QHLCGSHLVEALX⁴LVCGERGFX⁵YX⁶X⁷X⁸X⁹ en la que X¹ es F, Q o A; X² es V o G; X³ es N, K, D, G, Q, A o E; X⁴ es E, Y, Q, o H; X⁵ es H o F; X⁶ es G, T, S, H, V o está ausente; X⁷ es G, E, P, K, D, S, H o está ausente; X⁸ es G, E, K, P, Q, D, H o está ausente; X⁹ es G, T, S, E, K, A o está ausente, con la condición de que el análogo de la cadena B de insulina incluya por lo menos una modificación de la secuencia de aminoácidos de la cadena B de una molécula de insulina humana a X⁴, X⁵, X⁶, X⁷, X⁸, o X⁹ (SEC ID NUM.: 1); ii) Z² es un primer enlazador de péptidos que comprende de 5 a 10 aminoácidos, en la que por lo menos 5 de dichos aminoácidos son residuos de G; y iii) Z³ es un análogo de la cadena A de insulina que comprende la secuencia de aminoácidos: GIVEQCCTSX¹CSLX²QLENYCX³X⁴ en la que X¹ es T o l; X² es D, Y, Q o E; X³ es G, N, S o A; y X⁴ es cualquier aminoácido de origen natural, o está ausente, con la condición de que, si X³ es N, entonces X⁴ debe ser un aminoácido distinto de G o N (SEC ID NUM.: 2); b) un segundo enlazador de péptidos; y c) una región Fc de IgG humana; en el que el residuo C-terminal del agonista del receptor de insulina se fusiona directamente al residuo N-terminal del segundo enlazador de péptidos, y el residuo C-terminal del segundo enlazador de péptidos se fusiona directamente al residuo N-terminal de la región Fc de lgG humana. Reivindicación 16: Una composición farmacéutica que comprende ya sea una proteína de fusión de acuerdo con cualquiera de las reivindicaciones 1 a 14 o un homodímero de acuerdo con la reivindicación 15, y por lo menos un excipiente. Reivindicación 26: Un método para el tratamiento de un paciente con diabetes mellitus que comprende la administración a un paciente en necesidad del mismo una cantidad efectiva para uso terapéutico de la proteína de fusión de acuerdo con cualquiera de las reivindicaciones 1 a 14. Reivindicación 37: Un polinucleótido que codifica la proteína de fusión de acuerdo con cualquiera de las reivindicaciones 1 a 14.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562158079P | 2015-05-07 | 2015-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105616A1 true AR105616A1 (es) | 2017-10-25 |
Family
ID=55953435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160101082A AR105616A1 (es) | 2015-05-07 | 2016-04-20 | Proteínas de fusión |
Country Status (40)
| Country | Link |
|---|---|
| US (5) | US9855318B2 (es) |
| EP (1) | EP3292141B1 (es) |
| JP (1) | JP6591562B2 (es) |
| KR (1) | KR102059736B1 (es) |
| CN (1) | CN107531806B (es) |
| AR (1) | AR105616A1 (es) |
| AU (1) | AU2016257659B2 (es) |
| CA (1) | CA2981102A1 (es) |
| CL (1) | CL2017002761A1 (es) |
| CO (1) | CO2017011301A2 (es) |
| CR (1) | CR20170469A (es) |
| CY (1) | CY1122929T1 (es) |
| DK (1) | DK3292141T3 (es) |
| DO (1) | DOP2017000258A (es) |
| EA (1) | EA039770B1 (es) |
| EC (1) | ECSP17073650A (es) |
| ES (1) | ES2799099T3 (es) |
| HR (1) | HRP20200503T1 (es) |
| IL (1) | IL254965B (es) |
| JO (1) | JO3658B1 (es) |
| LT (1) | LT3292141T (es) |
| MA (1) | MA42037B1 (es) |
| MD (1) | MD3292141T2 (es) |
| ME (1) | ME03709B (es) |
| MX (1) | MX388594B (es) |
| MY (1) | MY183025A (es) |
| NZ (1) | NZ736470A (es) |
| PE (1) | PE20180507A1 (es) |
| PH (1) | PH12017502025A1 (es) |
| PL (1) | PL3292141T3 (es) |
| PT (1) | PT3292141T (es) |
| RS (1) | RS60044B1 (es) |
| SG (1) | SG11201708194WA (es) |
| SI (1) | SI3292141T1 (es) |
| SV (1) | SV2017005548A (es) |
| TN (1) | TN2018000059A1 (es) |
| TW (1) | TWI656132B (es) |
| UA (1) | UA122146C2 (es) |
| WO (1) | WO2016178905A1 (es) |
| ZA (1) | ZA201706334B (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016193380A1 (en) | 2015-06-02 | 2016-12-08 | Novo Nordisk A/S | Insulins with polar recombinant extensions |
| MA43348A (fr) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | Conjugués de protéines |
| MX2019001079A (es) | 2016-07-27 | 2019-09-18 | Hewlett Packard Development Co | Interfaz horizontal para cartucho de suministro de fluido que tiene sensores digitales de nivel de fluido. |
| EP3939605A1 (en) | 2016-12-09 | 2022-01-19 | Akston Biosciences Corporation | Insulin-fc fusions and methods of use |
| TR201703622A1 (tr) * | 2017-03-09 | 2018-09-21 | Univ Yeditepe | Obezi̇te tedavi̇si̇ i̇çi̇n bi̇r ürün |
| EP3606560A2 (en) | 2017-04-05 | 2020-02-12 | Novo Nordisk A/S | Oligomer extended insulin-fc conjugates |
| KR20200125590A (ko) | 2018-01-26 | 2020-11-04 | 제넨테크, 인크. | 조성물 및 사용 방법 |
| SG11202011460YA (en) | 2018-06-25 | 2020-12-30 | Univ Washington | De novo design of potent and selective interleukin mimetics |
| US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| DK4186920T5 (da) | 2018-06-29 | 2024-07-22 | Akston Biosciences Corp | Ultra-langtidsvirkende insulin-fc-fusionsproteiner og fremgangsmåder til anvendelse |
| WO2020074544A1 (en) | 2018-10-10 | 2020-04-16 | Novo Nordisk A/S | Oligomer extended insulin-fc conjugates and their medical use |
| US12234572B2 (en) | 2018-11-20 | 2025-02-25 | University Of Washington | Split interleukin mimetics and their use |
| JP7728176B2 (ja) * | 2019-03-15 | 2025-08-22 | イーライ リリー アンド カンパニー | 保存製剤 |
| WO2021011827A1 (en) * | 2019-07-16 | 2021-01-21 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
| TW202434620A (zh) | 2019-07-31 | 2024-09-01 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| AU2020368369A1 (en) | 2019-10-15 | 2022-05-12 | Eli Lilly And Company | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
| LT4073098T (lt) * | 2019-12-19 | 2023-12-11 | Akston Biosciences Corporation | Itin ilgai veikiantys insulino-fc sulieti baltymai ir jų naudojimo būdai |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| WO2021188374A2 (en) | 2020-03-16 | 2021-09-23 | Neoleukin Therapeutics, Inc. | Interleukin-2 receptor βeta (il-2rβ) binding polypeptides |
| WO2021207207A2 (en) | 2020-04-07 | 2021-10-14 | Neoleukin Therapeutics, Inc. | De novo protein decoys of angiotensin-converting enzyme 2 (ace2) |
| LT3972987T (lt) | 2020-04-10 | 2023-09-25 | Akston Biosciences Corporation | Antigenui specifinė imunoterapija, skirta sulietiems covid-19 baltymams ir naudojimo būdai |
| US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| JP7532638B2 (ja) * | 2020-07-24 | 2024-08-13 | チアンスー ジェンサイエンス インコーポレイテッド | インスリン－Ｆｃ融合タンパク質及びその応用 |
| EP4240407A1 (en) * | 2020-11-06 | 2023-09-13 | Amgen Inc. | Antigen binding domain with reduced clipping rate |
| KR20230118648A (ko) * | 2020-12-14 | 2023-08-11 | 일라이 릴리 앤드 캄파니 | 당뇨병을 치료하는 방법 |
| US11667689B2 (en) | 2021-07-23 | 2023-06-06 | Akston Biosciences Corporation | Insulin-Fc fusion proteins and methods of use to treat cancer |
| WO2023044318A2 (en) | 2021-09-15 | 2023-03-23 | Neoleukin Therapeutics, Inc. | Interleukin-2 receptor βeta (il-2rβ) binding polypeptides |
| AR127619A1 (es) * | 2021-11-15 | 2024-02-14 | Lilly Co Eli | FORMULACIONES CONSERVADAS DE FUSIONES DE INSULINA-Fc |
| JP2025509433A (ja) * | 2022-03-16 | 2025-04-11 | 北京拓界生物医薬科技有限公司 | ヒトインスリン類似体、その融合タンパク質及び医薬的使用 |
| CN119677541A (zh) | 2022-05-18 | 2025-03-21 | 原聚体科技公司 | 芳族含硼化合物和相关的胰岛素类似物 |
| JP2025522529A (ja) | 2022-06-23 | 2025-07-15 | サノフイ | 一本鎖インスリン及びそのＦｃ結合体 |
| WO2024137820A1 (en) * | 2022-12-20 | 2024-06-27 | The Board Of Trustees Of The Leland Stanford Junior University | Insulin receptor antagonist |
| CN115894720B (zh) * | 2023-01-16 | 2024-07-09 | 中国科学院上海药物研究所 | 一种长效胰岛素-Fc融合蛋白 |
| AU2024265269A1 (en) | 2023-05-03 | 2025-11-06 | Eli Lilly And Company | Methods and systems for managing diabetes |
| WO2025059010A1 (en) | 2023-09-11 | 2025-03-20 | Eli Lilly And Company | Methods and systems for managing diabetes |
| WO2025061146A1 (zh) * | 2023-09-20 | 2025-03-27 | 上海迈晋生物医药科技有限公司 | 一种人胰岛素类似物融合蛋白的药物组合物及其医药用途 |
| WO2025080923A1 (en) | 2023-10-13 | 2025-04-17 | Eli Lilly And Company | Insulin-fc fusion proteins |
| EP4669757A1 (en) | 2024-03-21 | 2025-12-31 | Akston Biosciences Corporation | PD-L1 ANALOGUE FUSION PROTEINS FOR ANTIGEN-SPECIFIC IMMUNOTHERAPY AND METHODS OF USE |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
| US5514646A (en) | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
| HU225496B1 (en) | 1993-04-07 | 2007-01-29 | Scios Inc | Pharmaceutical compositions of prolonged delivery, containing peptides |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| AU5724996A (en) | 1995-05-05 | 1996-11-21 | Eli Lilly And Company | Single chain insulin with high bioactivity |
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| AU5760900A (en) | 1999-06-25 | 2001-01-31 | Minimed, Inc. | Multiple agent diabetes therapy |
| KR100449454B1 (ko) | 2000-10-02 | 2004-09-21 | 이현철 | 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터 |
| JP2004528014A (ja) | 2000-12-07 | 2004-09-16 | イーライ・リリー・アンド・カンパニー | Ｇｌｐ−１融合タンパク質 |
| HUP0700126A2 (en) | 2001-12-20 | 2007-06-28 | Lilly Co Eli | Insulin molecule having protracted time action |
| US7452966B2 (en) * | 2003-06-12 | 2008-11-18 | Eli Lilly And Company | GLP-1 analog fusion proteins |
| JP4237755B2 (ja) | 2003-10-02 | 2009-03-11 | カール・ツァイス・エスエムティー・アーゲー | 半導体リソグラフィにおける光学的半組立品及び投射対物レンズ |
| ATE517119T1 (de) | 2003-12-03 | 2011-08-15 | Novo Nordisk As | Einzelketteninsulin |
| WO2006097521A1 (en) | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Pegylated single-chain insulin |
| EP1991575A1 (en) | 2006-02-21 | 2008-11-19 | Novo Nordisk A/S | Single-chain insulin analogues and pharmaceutical formulations thereof |
| EP1996223A1 (en) | 2006-03-13 | 2008-12-03 | Novo Nordisk A/S | Acylated single chain insulin |
| EP1996709A2 (en) | 2006-03-13 | 2008-12-03 | Novo Nordisk A/S | Acylated single chain insulin |
| AU2007298919C1 (en) | 2006-09-22 | 2014-02-06 | Novo Nordisk A/S | Protease resistant insulin analogues |
| ES2554773T3 (es) | 2006-10-04 | 2015-12-23 | Case Western Reserve University | Insulina y análogos de la insulina resistentes a la fibrilación |
| WO2008049711A1 (en) | 2006-10-27 | 2008-05-02 | Novo Nordisk A/S | Peptide extended insulins |
| JP5577243B2 (ja) * | 2007-05-30 | 2014-08-20 | ポステク アカデミー−インダストリー ファウンデイション | 免疫グロブリン融合タンパク質 |
| CN101730523A (zh) | 2007-07-10 | 2010-06-09 | 伊莱利利公司 | GLP-1-Fc融合蛋白质制剂 |
| EP2254905B1 (en) | 2008-03-14 | 2016-12-14 | Novo Nordisk A/S | Protease-stabilized insulin analogues |
| KR101755434B1 (ko) * | 2008-03-18 | 2017-07-10 | 노보 노르디스크 에이/에스 | 프로테아제 안정화되고, 아실화된 인슐린 유사체 |
| NZ588857A (en) | 2008-04-22 | 2012-07-27 | Univ Case Western Reserve | Isoform-specific insulin analogue for control blood sugar levels |
| GB0812019D0 (en) | 2008-07-02 | 2008-08-06 | Asterion Ltd | Insulin |
| CA2731546C (en) | 2008-07-23 | 2013-11-19 | Hanmi Holdings Co., Ltd. | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
| AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
| KR101324828B1 (ko) * | 2010-06-08 | 2013-11-01 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체 |
| CA2802485C (en) | 2010-06-16 | 2019-09-17 | Indiana University Research And Technology Corporation | Single chain insulin agonists exhibiting high activity at the insulin receptor |
| SG192671A1 (en) | 2011-02-09 | 2013-09-30 | Glaxosmithkline Llc | Lyophilized formulations |
| CN102718870B (zh) * | 2011-05-24 | 2014-04-30 | 马鞍山中美德康生物科技有限公司 | 一种胰岛素生物增敏剂及其应用 |
| UA113626C2 (xx) | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
| CN102516393B (zh) * | 2011-11-30 | 2017-03-15 | 北京康明百奥新药研发有限公司 | 胰岛素模拟肽融合蛋白和突变体及其应用 |
| CN103509118B (zh) * | 2012-06-15 | 2016-03-23 | 郭怀祖 | 胰岛素-Fc融合蛋白 |
| EP2869830B1 (en) | 2012-07-09 | 2016-10-12 | Novo Nordisk A/S | Novel use of insulin derivatives |
| AR091902A1 (es) | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
| AR092862A1 (es) | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
| CA2886228A1 (en) | 2012-09-26 | 2014-04-03 | Indiana University Research And Technology Corporation | Insulin analog dimers |
| BR112015010194B1 (pt) | 2012-11-05 | 2022-03-22 | Case Western Reserve University | Análogo de insulina de cadeia única, sequência de ácido nucleico e uso do mesmo |
| JP6465817B2 (ja) | 2013-02-26 | 2019-02-06 | ハンミ ファーム．カンパニー リミテッドＨａｎｍｉ Ｐｈａｒｍ．Ｃｏ．，Ｌｔｄ． | インスリン位置特異的結合体 |
| HK1220466A1 (zh) * | 2013-03-14 | 2017-05-05 | Regeneron Pharmaceuticals, Inc. | 爱帕琳融合蛋白和其用途 |
| RS57004B1 (sr) | 2013-10-07 | 2018-05-31 | Novo Nordisk As | Novi derivat analoga insulina |
| EP3098235A4 (en) | 2014-01-20 | 2017-10-18 | Hanmi Pharm. Co., Ltd. | Long-acting insulin and use thereof |
| AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| AR100695A1 (es) | 2014-05-30 | 2016-10-26 | Hanmi Pharm Ind Co Ltd | Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón |
| KR20160001391A (ko) | 2014-06-27 | 2016-01-06 | 한미약품 주식회사 | 신규한 지속형 인슐린 아날로그 결합체 및 이의 용도 |
| KR20160007295A (ko) | 2014-07-11 | 2016-01-20 | 한미약품 주식회사 | 인슐린 아날로그 |
| JP6829928B2 (ja) | 2014-10-06 | 2021-02-17 | ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ | 二相性単鎖インスリン類似体 |
| CR20170208A (es) | 2014-11-21 | 2017-07-17 | Merck Sharp & Dohme | Agonistas parciales del receptor de insulina |
| US10894089B2 (en) | 2015-02-17 | 2021-01-19 | Hanmi Pharm. Co., Ltd. | Long-acting insulin or insulin analogue conjugate |
| CN110134210A (zh) | 2019-04-16 | 2019-08-16 | 深圳市国鑫恒宇科技有限公司 | 一种服务器一体机的温度控制方法、系统、装置及存储介质 |
-
2016
- 2016-04-20 AR ARP160101082A patent/AR105616A1/es unknown
- 2016-04-21 JO JOP/2016/0076A patent/JO3658B1/ar active
- 2016-04-22 TW TW105112730A patent/TWI656132B/zh active
- 2016-04-28 KR KR1020177031825A patent/KR102059736B1/ko active Active
- 2016-04-28 RS RS20200326A patent/RS60044B1/sr unknown
- 2016-04-28 JP JP2017557346A patent/JP6591562B2/ja active Active
- 2016-04-28 PL PL16721605T patent/PL3292141T3/pl unknown
- 2016-04-28 MX MX2017014284A patent/MX388594B/es unknown
- 2016-04-28 EP EP16721605.0A patent/EP3292141B1/en active Active
- 2016-04-28 TN TNP/2018/000059A patent/TN2018000059A1/en unknown
- 2016-04-28 WO PCT/US2016/029807 patent/WO2016178905A1/en not_active Ceased
- 2016-04-28 PE PE2017002375A patent/PE20180507A1/es unknown
- 2016-04-28 ME MEP-2020-51A patent/ME03709B/me unknown
- 2016-04-28 CR CR20170469A patent/CR20170469A/es unknown
- 2016-04-28 AU AU2016257659A patent/AU2016257659B2/en active Active
- 2016-04-28 ES ES16721605T patent/ES2799099T3/es active Active
- 2016-04-28 US US15/140,519 patent/US9855318B2/en active Active
- 2016-04-28 HR HRP20200503TT patent/HRP20200503T1/hr unknown
- 2016-04-28 DK DK16721605.0T patent/DK3292141T3/da active
- 2016-04-28 UA UAA201710105A patent/UA122146C2/uk unknown
- 2016-04-28 MD MDE20180255T patent/MD3292141T2/ro unknown
- 2016-04-28 PT PT167216050T patent/PT3292141T/pt unknown
- 2016-04-28 CA CA2981102A patent/CA2981102A1/en active Pending
- 2016-04-28 LT LTEP16721605.0T patent/LT3292141T/lt unknown
- 2016-04-28 MY MYPI2017704174A patent/MY183025A/en unknown
- 2016-04-28 SG SG11201708194WA patent/SG11201708194WA/en unknown
- 2016-04-28 NZ NZ736470A patent/NZ736470A/en unknown
- 2016-04-28 SI SI201630651T patent/SI3292141T1/sl unknown
- 2016-04-28 CN CN201680023998.4A patent/CN107531806B/zh active Active
- 2016-04-28 EA EA201792199A patent/EA039770B1/ru unknown
- 2016-04-28 MA MA42037A patent/MA42037B1/fr unknown
-
2017
- 2017-09-19 ZA ZA2017/06334A patent/ZA201706334B/en unknown
- 2017-10-10 IL IL254965A patent/IL254965B/en active IP Right Grant
- 2017-10-17 SV SV2017005548A patent/SV2017005548A/es unknown
- 2017-10-31 CL CL2017002761A patent/CL2017002761A1/es unknown
- 2017-11-02 CO CONC2017/0011301A patent/CO2017011301A2/es unknown
- 2017-11-02 DO DO2017000258A patent/DOP2017000258A/es unknown
- 2017-11-06 EC ECIEPI201773650A patent/ECSP17073650A/es unknown
- 2017-11-07 PH PH12017502025A patent/PH12017502025A1/en unknown
- 2017-11-22 US US15/820,608 patent/US10709766B2/en active Active
-
2020
- 2020-03-16 CY CY20201100239T patent/CY1122929T1/el unknown
- 2020-06-05 US US16/893,498 patent/US11253574B2/en active Active
-
2022
- 2022-01-18 US US17/577,932 patent/US12059452B2/en active Active
-
2024
- 2024-06-27 US US18/756,062 patent/US20250032588A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105616A1 (es) | Proteínas de fusión | |
| US11998597B2 (en) | Vaccine against RSV | |
| CN107847581B (zh) | 稳定化的可溶性融合前rsv f多肽 | |
| PE20220283A1 (es) | Composicion farmaceutica para inyeccion subcutanea que comprende una variante de hialuronidasa humana ph20 y un medicamento | |
| PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
| AR070119A1 (es) | Derivados de insulina con perfil tiempo / accion extremadamente retardado | |
| HRP20231496T1 (hr) | Cistein proteaza | |
| MX2012002216A (es) | Nueva endolisina obpgplys. | |
| JP2018515088A5 (es) | ||
| JP2016512213A5 (es) | ||
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| RU2014101697A (ru) | Коагонисты рецепторов глюкагона/glp-1 | |
| AR091866A1 (es) | Analogos del glucagon | |
| CO6190536A2 (es) | Vacunas peptidicas para canceres que expresan antigenos asociados con tumores | |
| JP2013517783A5 (es) | ||
| JP2017522319A5 (es) | ||
| AR123187A1 (es) | Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer | |
| RU2017132689A (ru) | СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE | |
| WO2017207477A1 (en) | Stabilized pre-fusion rsv f proteins | |
| PE20220500A1 (es) | POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15 | |
| KR20240149405A (ko) | 키메라 폴리펩티드 | |
| KR20240149404A (ko) | 키메라 폴리펩티드 | |
| JP2019504119A5 (es) | ||
| HK40051815A (en) | Vaccine against rsv comprising modified f polypeptide | |
| JP2015522584A5 (es) |